AbbVie Inc. (ABBV)

NYQ – Real vaqt narxi. Valyuta: USD

207.86

+5.08 (2.51%)

Yopilishda: May 12, 2026, 4:01 PM EDT

208.28

+0.42 (0.20%)

Bozordan keyin: May 12, 2026, 8:00 PM EDT

09.05.2026

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

AbbVie NYSE: ABBV told shareholders at its annual meeting that 2025 was “another excellent year” for the company, citing record sales, stronger-than-expected revenue and continued investment in its drug pipeline and business development.

06.05.2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

06.05.2026

AbbVie to Present at the Bank of America Securities Healthcare Conference

NORTH CHICAGO, Ill., May 6, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Wednesday, May 13, 2026.

06.05.2026

Want Reliable Dividend Income in May? These 2 Stocks Deliver

AbbVie is a Dividend King that has proven its ability to adapt. Realty Income is the ultimate monthly income play.

05.05.2026

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

05.05.2026

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

AbbVie presents 18 abstracts in Crohn's disease and ulcerative colitis Breadth of data from real-world evidence and clinical trials reinforce risankizumab and upadacitinib efficacy, safety profile, and durability NORTH CHICAGO, Ill., May 5, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the presentation of new data across its gastroenterology portfolio at the 2026 Digestive Disease Week (DDW) Annual Meeting, May 2-5 in Chicago.

04.05.2026

AbbVie's Latest Results Reveal a Trend Investors Shouldn't Overlook

AbbVie posted strong first-quarter results. The company's two biggest growth drivers continue to exceed expectations.

Videolar

01.05.2026

Negative

AbbVie's Earnings Beat Wall Street's Estimates. Investors Are Still Worried

13.01.2026

Positive

AbbVie reaches 3-year deal with White House to lower drug prices

17.12.2025

Neutral

Final Trades: Abbvie Inc, Microsoft, Netflix and Twilio Inc

14.11.2025

Positive

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
ABBV	Citigroup	Neutral	undefined >> $205	May 14th 2025
ABBV	Cantor Fitzgerald	Overweight	undefined >> $210	April 22nd 2025
ABBV	Daiwa Securities	Neutral	undefined >> $180	December 5th 2024
ABBV	Leerink Partners	Outperform	undefined >> $206	November 22nd 2024
ABBV	Wolfe Research	Outperform	undefined >> $205	November 15th 2024
ABBV	Argus	Buy	undefined >> undefined	November 4th 2024
ABBV	Bernstein	Market Perform	undefined >> $203	October 17th 2024
ABBV	HSBC Securities	Buy	undefined >> $185	June 5th 2024

Press-relizlar

05.05.2026

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®

30.04.2026

Allergan Aesthetics Launches Philanthropic Effort in Recognition of Skin Cancer Awareness Month

Through its loyalty rewards program Allē, Allergan Aesthetics will donate to The Skin Cancer Foundation $10 for every new member who joins from a referral in May, up to $100,000. IRVINE, Calif.

29.04.2026

AbbVie Reports First-Quarter 2026 Financial Results

Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent; These Results Include an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Delivers First-Quarter Net Revenues of $15.002 Billion, an Increase of 12.4 Percent on a Reported Basis or 10.3 Percent on an Operational Basis First-Quarter Global Net Revenues from the Immunology Portfolio Were $7.290 Billion, an Increase of 16.4 Percent on a Reported Basis, or 14.3 Percent on an Operational Basis; Global Skyrizi Net Revenues Were $4.483 Billion; Global Rinvoq Net Revenues Were $2.119 Billion; Global Humira Net Revenues Were $688 Million First-Quarter Global Net Revenues from the Neuroscience Portfolio Were $2.875 Billion, an Increase of 26.0 Percent on a Reported Basis, or 24.3 Percent on an Operational Basis; Global Vraylar Net Revenues Were $905 Million; Global Botox Therapeutic Net Revenues Were $1.009 Billion; Combined Global Ubrelvy and Qulipta Net Revenues Were $635 Million; Global Vyalev Net Revenues Were $201 Million First-Quarter Global Net Revenues from the Oncology Portfolio Were $1.631 Billion, a Decrease of 0.2 Percent on a Reported Basis, or 3.0 Percent on an Operational Basis; Global Venclexta Net Revenues Were $770 Million; Global Imbruvica Net Revenues Were $556 Million; Global Elahere Net Revenues Were $198 Million First-Quarter Global Net Revenues from the Aesthetics Portfolio Were $1.186 Billion, an Increase of 7.6 Percent on a Reported Basis, or 5.1 Percent on an Operational Basis; Global Botox Cosmetic Net Revenues Were $668 Million; Global Juvederm Net Revenues Were $232 Million Raises 2026 Adjusted Diluted EPS Guidance Range from $13.96 - $14.16 to $14.08 - $14.28, which Includes an Unfavorable Impact of $0.41 Per Share Related to Acquired IPR&D and Milestones Expense Incurred Year-To-Date Through the First Quarter 2026 NORTH CHICAGO, Ill., April 29, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2026.

28.04.2026

AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata

Submission is supported by data from the Phase 3 UP-AA clinical program in which upadacitinib achieved the primary endpoint of severity of alopecia tool (SALT) score ≤ 20 at week 24, with additional efficacy results observed at week 52 1-3 Upadacitinib is also the first JAK inhibitor to meet the ranked secondary endpoint of complete scalp hair regrowth (SALT = 0) at week 24 1-3 NORTH CHICAGO, Ill., April 28, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for upadacitinib (RINVOQ®; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients with severe alopecia areata (AA), based on results from the Phase 3 UP-AA clinical program.1-3 "Alopecia areata is a chronic immune-mediated disease in which the physical and psychological burden patients can experience goes far beyond hair loss, impacting their day-to-day lives," said Kori Wallace, M.D.

AbbVie Inc. (ABBV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

AbbVie Inc. (ABBV)

AbbVie Touts Record Sales and Pipeline Momentum at Annual Meeting

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

AbbVie to Present at the Bank of America Securities Healthcare Conference

Want Reliable Dividend Income in May? These 2 Stocks Deliver

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week®